Alan has a degree in Finance from Birmingham University and is a chartered accountant. He is a founding partner of Bridgepoint Development Capital (BDC), where he sits on the Board and its Operating Committee, and is a member of its Investment Advisory Committee. Alan joined BDC in 1996 and is currently a board member for portfolio companies Monica Vinader and Analysys Mason. He has led a broad range of transactions, including public-to-private and serial international buy-and-build investments; previous transactions have included working with HKA, Matrix, Quotient Clinical, Phlexglobal, LOC Group, BigHand, The Energy Solutions Group, Pulsant and Safestore PLC. Prior to joining BDC, he worked for Deloitte (formerly Arthur Andersen) on its corporate finance team.
Featured
The Living Launch Plan: Keeping Pharma Launch Strategy Aligned
Discover how a living launch plan helps pharmaceutical teams adapt to evolving evidence, competitive dynamics, and changing market conditions.
News and insights
Featured
The New Drivers of Pharma Launch Uptake
Learn why precision in launch strategy is becoming essential for improving pharmaceutical launch uptake and commercial performance.
One-Size-Fits-All Launches Are Over
Read the article to discover why modern pharma launches require a precision approach, helping teams prioritize Must-Win Moments, reduce risk, and improve launch success.
ONWARD: Driving Equitable Access and System Readiness in Cancer Care
This Dolon Institute paper highlights six interconnected barriers affecting timely access to oncology innovation, drawing on examples from healthcare systems around the world.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
